Company: MDCXW
Filing Date: 2025-05-27
Form Type: S-1
Source: 0001062993-25-010333
Chunk: 203

Company: Medicus Pharma Ltd.
Filing Date: 2025-05-27
Form: S-1
Chunk 203
---
 Sale of Shares to the Selling 
         Shareholder Under the 
                          SEPA |
| $2.00                          |     |              3,604,160 |     | 23.4%                      |     |                    $7,208,320 |
| $2.80(3)                       |     |              3,604,160 |     | 23.4%                      |     |                   $10,091,648 |
| $3.00                          |     |              3,604,160 |     | 23.4%                      |     |                   $10,812,480 |
| $4.00                          |     |              3,604,160 |     | 23.4%                      |     |                   $14,416,640 |
| $5.00                          |     |              3,000,000 |     | 20.2%                      |     |                   $15,000,000 |
| $6.00                          |     |              2,500,000 |     | 17.5%                      |     |                   $15,000,000 |
| $7.00                          |     |              2,142,857 |     | 15.4%                      |     |                   $15,000,000 |

__________________

(1)Does not include 105,840 Commitment Shares that we issued to the Selling Shareholder as consideration for its commitment to purchase common shares under the SEPA. The number of common shares offered by this prospectus may not cover all the shares we ultimately sell to the Selling Shareholder under the SEPA, depending on the purchase price per share. We have included in this column only those shares being offered for resale by the Selling Shareholder under this prospectus (excluding the 105,840 Commitment Shares), without regard for the Exchange Cap or the Ownership Limitation. The assumed average purchase prices are solely for illustration and are not intended to be estimates or predictions of future share performance.

(2)The denominator is based on 11,816,721 common shares outstanding as of February 10, 2025, adjusted to include the issuance of the number of common shares set forth in the second column that we would have sold to the Selling Shareholder, assuming the average purchase price in the first column. The numerator is based on the number of common shares set forth in the second column.

(3)Represents the closing price of the common shares on the Nasdaq